Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer

Published:2011 Issue:2 Volume:57 Page:147-155
ISSN:1421-9794
Container-title:Chemotherapy
language:en
Short-container-title:Chemotherapy

Author:

Chung Fu-Tsai,Lee Kang-Yun,Fang Yueh-Fu,Shieh Meng-Heng,Lin Shu-Min,Yu Chih-Teng,Lo Yun-Lun,Lin Ting-Yu,Kuo Chih-Hsi,Feng Po-Hao,Ni Yung-Lun,Kuo Han-Pin

Publisher

S. Karger AG

Subject

Infectious Diseases,Pharmacology (medical),Drug Discovery,Pharmacology,Oncology,General Medicine

Reference30 articles.

1. Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results

2. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

3. Locally Advanced, Unresectable Non-Small Cell Lung Cancer

4. Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

5. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer;Frontiers in Immunology;2023-09-18

2. Treatment outcome of patients with co-existing TB and LC: systematic reviews and meta-analysis;2023-02-06

3. Cytotoxics and Anti-angiogenics: Metronomic Therapies;Tumor Angiogenesis;2019

4. Cytotoxics and Anti-Angiogenics: Metronomic Therapies;Tumor Angiogenesis;2017

5. Quantitative and qualitative assessment of real world data comparative effectiveness research of systemic therapies in lung oncology: A systematic review;Cancer Epidemiology;2016-10